Divis Laboratories share price
Divis Laboratories is trading 0.51% upper at Rs 4,935.50 as compared to its last closing price. Divis Laboratories has been trading in the price range of 4,944.15 & 4,801.00. Divis Laboratories has given 25.83% in this year & 8.51% in the last 5 days.
Divis Laboratories has TTM P/E ratio 57.17 as compared to the sector P/E of 50.57.There are 22 analysts who have initiated coverage on Divis Laboratories. There are 3 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 6 analysts have given the stock a sell rating.
The company posted a net profit of 538.00 Crores in its last quarter.
Listed peers of Divis Laboratories include Sun Pharmaceutical Industries (0.95%), Divis Laboratories (0.51%), Cipla (0.86%) etc.
Divis Laboratories has a 51.90% promoter holding & 48.10% public holding.The Mutual Fund holding in Divis Laboratories was at 8.03% in 30 Jun 2024. The MF holding has increased from the last quarter. The FII holding in Divis Laboratories was at 16.16% in 30 Jun 2024. The FII holding has increased from the last quarter.
Divis Laboratories share price range
|
| ||||
|
| ||||
Divis Laboratories share Key Metrics
Market Cap ( ₹ Cr.) | 1,30,407.50 | ||||||||||||||||||
|
|
Divis Laboratories stock Analysis
1 Week | 8.51% |
3 Months | 22.74% |
6 Month | 38.31% |
YTD | 25.83% |
1 Year | 33.33% |
- 25%Moderate risk
- 25%Moderate risk
- 25%Moderate risk
- 25%Moderate risk
- 25%Moderate risk
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Ratings | Current | 1 W Ago | 1 M Ago | 3 M Ago |
---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 |
Hold | 7 | 7 | 7 | 4 |
Sell | 6 | 6 | 6 | 8 |
Strong Sell | 5 | 5 | 5 | 5 |
Total | 22 | 22 | 22 | 21 |
Technical Trends
Long TermConsiders price movement over the last 6 months
Short TermConsiders price movement over the last 1-2 weeks
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Divis Laboratories share price news
JM Financial anticipates Trent, BEL to join Nifty50 in August indices rebalancing
2 min read .07:37 PM ISTQ3 results today: ONGC, Divis Laboratories, Aurobindo Pharma, MCX and more in focus
1 min read .07:59 AM ISTDivis Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
Period | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
Total Revenue | 7,845.00 | 7,767.51 | 8,959.83 | 6,969.40 |
Selling/ General/ Admin Expenses Total | 1,094.00 | 1,654.40 | 1,541.48 | 1,306.00 |
Depreciation/ Amortization | 378.00 | 343.18 | 311.51 | 255.59 |
Other Operating Expenses Total | 1,417.00 | - | - | - |
Total Operating Expense | 6,018.00 | 5,741.74 | 5,387.35 | 4,354.71 |
Operating Income | 1,827.00 | 2,025.77 | 3,572.48 | 2,614.69 |
Net Income Before Taxes | 2,163.00 | 2,368.63 | 3,683.50 | 2,666.04 |
Net Income | 1,600.00 | 1,823.38 | 2,960.45 | 1,984.29 |
Diluted Normalized EPS | 60.27 | 68.72 | 111.58 | 74.91 |
Divis Laboratories forecast
Divis Laboratories Technical
5 Day 4,666.32 |
10 Day 4,610.91 |
20 Day 4,589.14 |
50 Day 4,435.87 |
100 Day 4,044.67 |
300 Day 3,871.29 |
Divis Laboratories Futures and Options
- FUTURES
- OPTIONS
Share Price
4,910.00INR7.55(0.15%)Open Interest
2.48 MINR1.49 L(6.89%)
- Open4,875.25
- High4,930.95
- Low4,783.00
- Prev Close4,902.45
- Contracts Traded10.81 K
- Turnover in (Rs Lakhs)1.05 L
Divis Laboratories Corporate actions
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
Meeting Date | Purpose |
03-Aug-24 | Quarterly Results |
25-May-24 | Audited Results & Dividend |
10-Feb-24 | Quarterly Results |
06-Nov-23 | Quarterly Results |
14-Aug-23 | Quarterly Results |
20-May-23 | Audited Results & Final Dividend |
03-Feb-23 | Quarterly Results |
07-Nov-22 | Quarterly Results |
12-Aug-22 | Quarterly Results |
23-May-22 | Audited Results & Dividend |
Meeting Date | Announcement On | Purpose |
28-Aug-23 | 20-May-23 | AGM |
22-Aug-22 | 04-Jul-22 | AGM |
28-Mar-22 | 24-Feb-22 | POM |
30-Aug-21 | 02-Aug-21 | AGM |
Announcement On | Record Date | Ex-Dividend | Dividend Value |
27-May-24 | 02-Aug-24 | 02-Aug-24 | 30 |
22-May-23 | 11-Aug-23 | 11-Aug-23 | 30 |
23-May-22 | 12-Aug-22 | 11-Aug-22 | 30 |
31-May-21 | - | 17-Aug-21 | 20 |
Divis Laboratories Company profile
ABOUT Divis Laboratories
- Industry Biotechnology & Drugs
- ISIN INE361B01024
- BSE Code 532488
- NSE Code DIVISLAB
Divi's Laboratories Limited is an India-based company, which is engaged in pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl, Vigabatrin, and others. The Company is also engaged in custom synthesis (contract manufacturing services) of APIs and Intermediates for global innovator companies with a portfolio of products across diverse therapeutic areas. The Company’s subsidiaries include Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG.
Divis Laboratories Management
- Kiran Divi Chief Executive Officer, Whole-time Director
- L. Kishore Babu Chief Financial Officer
- M. Satish Choudhury Compliance Officer, Company Secretary
- Murali Divi Managing Director, Executive Director
- Nilima Divi Whole-Time Director - (Commercial)
- Nimmagadda Ramana Executive Director
- S. Devendra Rao Whole-time Director (Manufacturing)
FAQs about Divis Laboratories share price
Divis Laboratories Quick Links
Divis Laboratories Dividend Divis Laboratories Bonus Divis Laboratories News Divis Laboratories AGM Divis Laboratories Rights Divis Laboratories Splits Divis Laboratories Board Meetings Divis Laboratories Key Metrics Divis Laboratories Shareholdings Divis Laboratories Profit Loss Divis Laboratories Balance Sheet Divis Laboratories Cashflow Divis Laboratories Q1 Results Divis Laboratories Q2 Results Divis Laboratories Q3 Results Divis Laboratories Q4 Results
Equity Quick Links
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks